Kovesdy, Csaba
Schmedt, Niklas
Folkerts, Kerstin
Bowrin, Kevin
Raad, Hanaya
Batech, Michael
Fried, Linda
Funding for this research was provided by:
Bayer
Article History
Received: 12 August 2021
Accepted: 17 November 2021
First Online: 10 January 2022
Declarations
:
: No patient’s personal identifying information is included in this manuscript. All data used for this study were accessed with protocols compliant with US patient confidentiality requirements, including the Health Insurance Portability and Accountability Act of 1996 regulations. Because this study was non-interventional and used only statistically de-identified patient records, it was exempt from institutional review board review.
: All images included in this study are entirely unidentifiable and there are no details on individuals reported within the manuscript; therefore, consent for publication of images is not required.
: LF received honoraria for consultant work from Bayer, DSMB: Novonordisk, and CSL Behring. CK received honoraria for consultant work from Abbott, Akebia, AstraZeneca, Bayer, Cara Therapeutics, CSL Behring, Rockwell, and Vifor. KB, KF, and NS are employees of Bayer. HR, MB, and AF were employees of Aetion and owned stock options at the time this work was conducted.